Plain-English translation of NCT04329728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
The OPAL Study is testing a new medication called to treat lymphoid malignancies—serious blood cancers including leukemias and lymphomas that have returned or stopped responding to previous treatments. This trial will give the medication by infusion to patients with different types of these cancers to see how safe and effective the treatment is. Researchers want to find the best dose and schedule for giving this medication repeatedly over time.
Many patients with advanced blood cancers run out of standard treatment options when their disease returns or becomes resistant to existing therapies. This trial aims to offer a new treatment possibility and to understand whether this medication can help patients for whom other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion every 21 days (about once every 3 weeks) at a research clinic, continuing until the cancer progresses, side effects become too difficult to manage, or you cannot tolerate the treatment anymore. The trial includes regular blood tests and assessments to monitor how well the medication is working and any side effects you might experience. Some patients will have extra blood draws early in the trial to help researchers understand how your body processes the medication.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States